Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. 2007

Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
Department of Cardiology, The First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong 515041, China.

There is a striking gender difference in atherosclerotic vascular disease. For decades, testosterone was considered detrimental to the cardiovascular system. Recent studies, however, have presented some alternative results. The aim of this study was to evaluate the effect of testosterone, using physiological and supraphysiological concentrations, on antigen and mRNA levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), and tissue factor pathway inhibitor (TFPI) released by human umbilical vein endothelial cells and to investigate the cellular mechanism. Cells within 2-3 passages were cultured in 25 cm(2) flasks or plated onto 96-well plates with a density of about 1 x 10(5) cells/mL as recommended. The cells were incubated in the presence or absence of testosterone (3, 30, 3 x 10(3), 3 x 10(4) nmol/L) for 48 h. Levels of tPA, PAI-1, and TFPI antigen were assayed with ELISA kits. Reverse transcriptase PCR was carried out to detect tPA, PAI-1, and TFPI mRNA levels. Cells were incubated in androgen-receptor antagonist (flutamide 10 micromol/L) or aromatase inhibitor (aminoglutethimide 50 micromol/L) for 3 h, and then the experiments were repeated. Testosterone at a physiologic concentration (30 nmol/L) increased the antigen levels of tPA and TFPI significantly (P < 0.05). However, tPA and TFPI levels were markedly reduced (P < 0.05) at a larger dose (3 x 10(4) nmol/L). On the other hand, PAI-1 antigen levels decreased significantly at the testosterone concentrations ranging from 3 to 3 x 10(4) nmol/L (P < 0.05). The change in the levels of tPA and TFPI were reflected in the corresponding change in mRNA levels. Flutamide attenuated the effect of testosterone at physiological concentration (30 nmol/L). The results demonstrated that testosterone at physiological concentrations may have a beneficial influence on the haemostatic system through enhancement of anticoagulant activity, resulting from stimulation of TFPI and tPA expression and inhibition of PAI-1 secretion by the endothelium.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005485 Flutamide An antiandrogen with about the same potency as cyproterone in rodent and canine species. Niftolid,Apimid,Apo-Flutamide,Chimax,Cytamid,Drogenil,Euflex,Eulexin,Eulexine,Fluken,Flulem,Flumid,Fluta 1A Pharma,Fluta-GRY,Fluta-cell,Flutamin,Flutandrona,Flutaplex,Flutexin,Fugerel,Grisetin,Niftolide,Novo-Flutamide,Oncosal,PMS-Flutamide,Prostacur,Prostica,Prostogenat,SCH-13521,Testotard,Apo Flutamide,ApoFlutamide,Fluta GRY,Fluta cell,FlutaGRY,Flutacell,Novo Flutamide,NovoFlutamide,PMS Flutamide,SCH 13521,SCH13521
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000726 Androgen Antagonists Compounds which inhibit or antagonize the biosynthesis or actions of androgens. Androgen Antagonist,Antiandrogen,Antiandrogens,Anti-Androgen Effect,Anti-Androgen Effects,Antiandrogen Effect,Antiandrogen Effects,Antagonist, Androgen,Antagonists, Androgen,Anti Androgen Effect,Anti Androgen Effects,Effect, Anti-Androgen,Effect, Antiandrogen,Effects, Anti-Androgen,Effects, Antiandrogen
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen

Related Publications

Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
July 2000, Thrombosis and haemostasis,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
July 1994, Blood,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
June 1997, Thrombosis and haemostasis,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
October 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
December 1984, The Journal of clinical investigation,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
August 1993, Circulation research,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
April 1994, Thrombosis research,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
February 1988, The Journal of biological chemistry,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
November 1988, The Journal of biological chemistry,
Hong Jin, and Jijin Lin, and Lu Fu, and Yi-Fang Mei, and Geng Peng, and Xuerui Tan, and Dong-Ming Wang, and Wei Wang, and Yu-Guang Li
September 1993, Thrombosis and haemostasis,
Copied contents to your clipboard!